📊 NVCR Key Takeaways
Is NovoCure Ltd (NVCR) a Good Investment?
NovoCure demonstrates exceptional 77.6% gross margins and improving profitability (21.8% EPS improvement YoY) indicative of strong product-market fit, but remains deeply unprofitable with -$67.4M operating losses and negative free cash flow of -$18.7M, creating a ~4-5 year cash runway that requires sustained revenue growth and rapid path to operating leverage.
NovoCure shows strong unit economics with a 74.5% gross margin and steady 8.3% revenue growth, indicating a resilient revenue base. However, persistent operating losses, negative free cash flow, and weak interest coverage weigh on fundamentals despite solid liquidity. A clearer path to operating leverage and cash generation is needed before improving the outlook.
Why Buy NovoCure Ltd Stock? NVCR Key Strengths
- Exceptional 77.6% gross margin reveals strong pricing power and product differentiation in medical device market
- Revenue growth of 8.3% YoY demonstrates expanding customer base and market adoption
- Profitability rapidly improving with 21.8% YoY EPS improvement, showing operational trajectory toward breakeven
- Strong liquidity position with 2.90x current ratio and $87.5M cash reserves
- Moderate leverage at 0.59x debt/equity ratio preserves financial flexibility
- High gross margin (74.5%) supporting potential operating leverage
- Solid liquidity (current 2.9x, quick 2.71x) with moderate leverage (D/E 0.57x)
- Consistent revenue growth (+8.3% YoY)
NVCR Stock Risks: NovoCure Ltd Investment Risks
- Operating losses of -$67.4M (-38.7% margin) reveal massive operating expense burden despite high gross profit
- Negative free cash flow of -$18.7M creates ongoing cash burn with limited runway before capital constraints emerge
- Cannot cover interest expense from operations (interest coverage -3.0x), dependent on cash reserves to service debt
- ROE of -21.5% and ROA of -9.0% indicate shareholder value destruction and inefficient asset deployment
- Path to profitability unproven; requires significant operating expense reduction or accelerated revenue growth
- Sustained operating and net losses (operating margin -23.5%, net margin -20.8%)
- Negative free cash flow and ongoing cash burn
- Weak interest coverage (-6.9x) raises refinancing and solvency risks if losses persist
Key Metrics to Watch
- Operating margin trend toward breakeven and EBITDA conversion to positive
- Free cash flow narrowing and inflection toward positive cash generation
- Revenue growth sustainability and whether it accelerates to justify current burn rate
- Operating expense as percentage of revenue and SG&A/R&D spending discipline
- Cash runway depletion rate and whether Company achieves profitability before capital constraints
- Operating margin
- Free cash flow
NovoCure Ltd (NVCR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.90x current ratio provides a solid financial cushion.
NVCR Profit Margin, ROE & Profitability Analysis
NVCR vs Healthcare Sector: How NovoCure Ltd Compares
How NovoCure Ltd compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is NovoCure Ltd Stock Overvalued? NVCR Valuation Analysis 2026
Based on fundamental analysis, NovoCure Ltd shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
NovoCure Ltd Balance Sheet: NVCR Debt, Cash & Liquidity
NVCR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: NovoCure Ltd's revenue has grown significantly by 22% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.95 indicates the company is currently unprofitable.
NVCR Revenue Growth, EPS Growth & YoY Performance
NVCR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $155.0M | -$34.3M | $-0.31 |
| Q3 2025 | $155.1M | -$30.6M | $-0.28 |
| Q2 2025 | $150.4M | -$33.4M | $-0.31 |
| Q1 2025 | $138.5M | -$34.3M | $-0.31 |
| Q3 2024 | $127.3M | -$30.6M | $-0.28 |
| Q2 2024 | $126.1M | -$33.4M | $-0.31 |
| Q1 2024 | $122.2M | -$38.8M | $-0.36 |
| Q3 2023 | $127.3M | -$4.6M | $-0.25 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
NovoCure Ltd Dividends, Buybacks & Capital Allocation
NVCR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for NovoCure Ltd (CIK: 0001645113)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NVCR
What is the AI rating for NVCR?
NovoCure Ltd (NVCR) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 61% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NVCR's key strengths?
Claude: Exceptional 77.6% gross margin reveals strong pricing power and product differentiation in medical device market. Revenue growth of 8.3% YoY demonstrates expanding customer base and market adoption. ChatGPT: High gross margin (74.5%) supporting potential operating leverage. Solid liquidity (current 2.9x, quick 2.71x) with moderate leverage (D/E 0.57x).
What are the risks of investing in NVCR?
Claude: Operating losses of -$67.4M (-38.7% margin) reveal massive operating expense burden despite high gross profit. Negative free cash flow of -$18.7M creates ongoing cash burn with limited runway before capital constraints emerge. ChatGPT: Sustained operating and net losses (operating margin -23.5%, net margin -20.8%). Negative free cash flow and ongoing cash burn.
What is NVCR's revenue and growth?
NovoCure Ltd reported revenue of $174.1M.
Does NVCR pay dividends?
NovoCure Ltd does not currently pay dividends.
Where can I find NVCR SEC filings?
Official SEC filings for NovoCure Ltd (CIK: 0001645113) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NVCR's EPS?
NovoCure Ltd has a diluted EPS of $-0.62.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NVCR a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, NovoCure Ltd has a HOLD rating with 61% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NVCR stock overvalued or undervalued?
Valuation metrics for NVCR: ROE of -21.5% (sector avg: 15%), net margin of -40.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NVCR stock in 2026?
Our dual AI analysis gives NovoCure Ltd a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NVCR's free cash flow?
NovoCure Ltd's operating cash flow is $-13.5M, with capital expenditures of $5.2M. FCF margin is -10.7%.
How does NVCR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -40.9% (avg: 12%), ROE -21.5% (avg: 15%), current ratio 2.90 (avg: 2).